Share-based Payment Arrangement, Expense of Jade Biosciences, Inc. from 30 Jun 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Jade Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 31 Dec 2025.
  • Jade Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $10,634,000, a 756% increase year-over-year.
  • Jade Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $20,009,000, a 77% increase year-over-year.
  • Jade Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $20,009,000, a 77% increase from 2024.
  • Jade Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $11,311,000, a 5% decline from 2023.
  • Jade Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11,906,000, a 117% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Jade Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $20,009,000 $10,634,000 +$9,391,000 +756% 01 Oct 2025 31 Dec 2025 10-K 06 Mar 2026 2025 FY
Q3 2025 $10,618,000 $4,295,000 +$2,292,000 +114% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $8,326,000 $3,895,000 +$30,000 +0.78% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $8,296,000 $1,185,000 -$3,015,000 -72% 01 Jan 2025 31 Mar 2025 10-Q 25 Apr 2025 2025 Q1
Q4 2024 $11,311,000 $1,243,000 -$2,008,000 -62% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $13,319,000 $2,003,000 -$1,234,000 -38% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $14,553,000 $3,865,000 +$831,000 +27% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $13,722,000 $4,200,000 +$1,816,000 +76% 01 Jan 2024 31 Mar 2024 10-Q 25 Apr 2025 2025 Q1
Q4 2023 $11,906,000 $3,251,000 +$1,522,000 +88% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $10,384,000 $3,237,000 +$1,738,000 +116% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $8,646,000 $3,034,000 +$1,810,000 +148% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $6,836,000 $2,384,000 +$1,360,000 +133% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $5,476,000 $1,729,000 +$875,000 +102% 01 Oct 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 $4,601,000 $1,499,000 +$654,000 +77% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $3,947,000 $1,224,000 +$903,000 +281% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $3,044,000 $1,024,000 +$1,001,000 +4352% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $2,043,000 $854,000 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $845,000 +$824,000 +3924% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $321,000 +$315,000 +5250% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $23,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $21,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $6,000 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2

Jade Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $20,009,000 +$8,698,000 +77% 01 Jan 2025 31 Dec 2025 10-K 06 Mar 2026 2025 FY
2024 $11,311,000 -$595,000 -5% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $11,906,000 +$6,430,000 +117% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $5,476,000 +$3,433,000 +168% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
2021 $2,043,000 +$1,985,000 +3422% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $58,000 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.